Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effects of Root Extract Ashwagandha (KSM-66) on Perception of Recovery and Muscle Strength in Adolescents Aged 11 to 19 Engaged in Grassroots Football

12 de novembro de 2026 atualizado por: Alex Levington, Sports Performance and Applied Research in Trials and Analysis

Effects of KSM-66 Ashwagandha (Withania Somnifera) Root Extract Supplementation on Perception of Recovery and Muscle Strength in Adolescents in Grassroots Football: A Randomised, Double-Blind, Placebo-Controlled Trial

This study will test whether six weeks of ashwagandha (KSM-66 root extract), helps teenage footballers recover and improve strength. Very little research has looked at young people aged 11 to 19, despite increased usage in this cohort.

About 50 to 60 male and female players from grassroots clubs in Sussex, Surrey and Greater London will be randomly assigned to take a daily capsule of either 450 mg ashwagandha or a placebo in an unblinded fashion. Before and after the six weeks, players will do tests at their usual training site: saliva samples to measure the cortisol, grip strength, a 1 km time trial, and short questionnaires on recovery, sleep, stress and soreness.

The results will show whether ashwagandha changes stress, strength, performance and perceived recovery over six weeks.

Visão geral do estudo

Descrição detalhada

This randomised, double-blind, placebo-controlled trial will test whether KSM-66 ashwagandha (Withania somnifera) root extract alters physiological stress, neuromuscular performance and perceived recovery in adolescent footballers. In adults, standardised root extract has been associated with improved strength, recovery, sleep and reduced cortisol. In children, the only placebo-controlled trial of root extract (ages 6 to 12) examined cognition and sleep. No trial has studied adolescents, whose growth, maturation and training load may alter responses, so adult findings cannot be assumed to apply.

An independent collaborator outside the research team will generate the allocation (block size four, stratified by sex and age band, 11 to 15 and 16 to 19) and label bottles with participant codes only. Participants, caregivers and investigators will remain blind until the dataset is locked, and blinding success will be assessed at follow-up. Players aged 11 to 15 take part with parental consent and their own assent, and players aged 16 to 19 consent for themselves. A study medical official will screen medical eligibility. Caregivers or participants will be contacted weekly regarding adverse events, and any suspected supplement-related event will lead to discontinuation and medical review within 24 hours.

Data will be analysed by linear mixed methods. Two investigators will analyse the coded data independently and blind to allocation. Results will be interpreted as short-term responses and will not establish long-term safety or efficacy.

Tipo de estudo

Intervencional

Inscrição (Estimado)

60

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

11 anos a 19 anos (Filho, Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Aged 11 to 19 years on the day of baseline testing
  • Male or female player registered with a participating grassroots football club or community football programme, taking part in organised football training at least once a week (any playing ability)
  • Able to attend both testing sessions and able to swallow a capsule
  • Valid written consent: parent/caregiver consent and player assent (ages 11 to 17), or the player's own consent (ages 18 to 19)

Exclusion Criteria:

  • Diagnosed liver, kidney or thyroid condition
  • Autoimmune condition (e.g. type 1 diabetes, lupus, rheumatoid or juvenile idiopathic arthritis, inflammatory bowel disease)
  • Diabetes or another condition affecting blood sugar; high or low blood pressure requiring treatment
  • Regularly taking prescribed medication
  • Known allergy or intolerance to ashwagandha, nightshade family plants, corn (maize) or the capsule shell
  • Pregnant, possibly pregnant or breastfeeding
  • Stomach ulcer; heart condition; chest pain, fainting or seizures during exercise; or medical advice not to do hard exercise
  • Current illness or injury that prevents maximal effort
  • Surgery planned during the study or within 2 weeks after it, or hospital admission in the last 3 months
  • Currently taking, or taken in the past 4 weeks, ashwagandha in any form, including combination products
  • Unwilling to avoid starting any new supplement during the six weeks
  • Taking part in another research study involving a supplement or medicine in the past 3 months

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Root extract Ashwagandha

450mg of KSM-66 Ashwagandha

One 450 mg capsule of KSM-66 ashwagandha, taken once daily with a meal for six weeks (42 days). KSM-66 is a full-spectrum extract made from root only, with no leaf, standardised to 5% withanolides (HPLC verified), and supplied with a certificate of analysis for each batch. Capsules are supplied in labelled bottles of 42 and are identical in appearance to the placebo.

Outros nomes:
  • KSM-66
Comparador de Placebo: Placebo

450mg corn starch

One 450 mg capsule of corn starch, taken once daily with a meal for six weeks (42 days). The capsule shell, appearance, bottle and labelling are identical to the active capsule.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Salivary cortisol
Prazo: Baseline (week 0) and after six weeks of supplementation

Saliva collected with Salivette tubes after an evening training session and analysed by an external laboratory. Reported as the change from baseline to follow-up.

Baseline (week 0) and after six weeks of supplementation

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Salivary alpha-amylase
Prazo: Baseline (week 0) and after six weeks of supplementation

Measured from the same saliva samples as cortisol.

Baseline (week 0) and after six weeks of supplementation
Handgrip Strength
Prazo: Baseline (week 0) and after six weeks of supplementation

Maximal handgrip strength measured with a CAMRY handgrip dynamometer.

Baseline (week 0) and after six weeks of supplementation
Number of participants with adverse events
Prazo: Baseline (week 0) and after six weeks of supplementation

Any adverse events reported in the duration of the clinical trial

Baseline (week 0) and after six weeks of supplementation
Change in perceived recovery, measured by the Hooper Index
Prazo: Baseline (week 0) and after six weeks of supplementation

Self-reported fatigue, stress, sleep quality and muscle soreness on the Hooper Index questionnaire. Individual items are scored 1 (very, very good) to 10 (very, very bad) and the total score is 4 to 40, higher scores indicating poorer recovery.

Baseline (week 0) and after six weeks of supplementation
Change in 1 km time-trial performance
Prazo: Baseline (week 0) and after six weeks of supplementation

Time taken to complete a 1 km run, as a measure of aerobic fitness and high-intensity running capacity.

Baseline (week 0) and after six weeks of supplementation

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

20 de dezembro de 2026

Conclusão do estudo (Estimado)

20 de dezembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

14 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de outubro de 2026

Primeira postagem (Real)

22 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • ASH-ADOL-001

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared. Participants will be minors recruited from a small number of local football clubs, so a dataset of this size (about 50 to 60 players) combined with age, sex and test results could allow re-identification even after coding. Consent and assent were obtained for use of the data within this study only, and the participant code key and contact details will be permanently deleted on 31 May 2027. The fully anonymised dataset will be held securely by the research team and used only for the analyses and publications described in the ethics-approved protocol. Summary results will be reported in the results section of this record and in peer-reviewed publication, with participating clubs not named.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever